A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes

References

• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-17
   PubMed Web of Science ®Google Scholar
• Sicras A, Rejas J, Arco S, et al. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord 2005;19:305-15
   PubMed Web of Science ®Google Scholar
• Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006;21:175-81
   PubMed Web of Science ®Google Scholar
• McDowell I, Hill G, Lindsay J, et al. Canadian study of health and aging - study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913
   Web of Science ®Google Scholar
• Lilienfeld S, Kurz A. Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine. Alzheimer's Dis Vasc Etiol Pathol 2002;977:487-92
   Google Scholar
• Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract 2003;57:219-23
   PubMed Web of Science ®Google Scholar
• Bennett D. Public health importance of vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract 2001;120:41-8
   Google Scholar
• Fillit H, Hill J. The costs of vascular dementia: a comparison with Alzheimer's disease. J Neurol Sci 2002;203:35-9
   PubMed Web of Science ®Google Scholar
• Roman G. Managing Vascular Dementia: concepts, Issues and Management. London: Science Press, 2003
   Google Scholar
• Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16:203-12
   PubMed Web of Science ®Google Scholar
• Selnes OA, Vinters HV. Vascular cognitive impairment. Nature Clin Pract Neurol 2006;2:538-47
   PubMedGoogle Scholar
• Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Eng J Med 2001;344:1111-16
   PubMed Web of Science ®Google Scholar
• Aguero-Torres H, Fratiglioni L, Guo Z, et al. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737-43
   PubMed Web of Science ®Google Scholar
• Aevarsson O, Svanborg A, Skoog I. Seven-year survival rate after age 85 years - relation to Alzheimer disease and vascular dementia. Arch Neurol 1998;55:1226
   PubMed Web of Science ®Google Scholar
• Tatemichi TK, Paik M, Bagiella E, et al. Dementia after stroke is a predictor of long-term survival. Stroke 1994;25:1915-19
   PubMed Web of Science ®Google Scholar
• Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?. Am J Geriatr Pharmacother 2005;3:1-7
   PubMedGoogle Scholar
• Brashear HR. Galantamine in the treatment of vascular dementia. Int Psychogeriatr 2003;15:187-93
   PubMed Web of Science ®Google Scholar
• Schindler RJ. Dementia with cerebrovascular disease: the benefits of early treatment. Eur J Neurol 2005;12:17-21
   PubMed Web of Science ®Google Scholar
• Hux MJ, O’Brien RJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and cost of caring. Can Med Assoc J 1998;459:457-65
   Google Scholar
• Rockwood K, Brown M, Merry H, et al. Societal costs of vascular cognitive impairment in older adults. Stroke 2002;33:1605-9
   PubMed Web of Science ®Google Scholar
• Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiologic research - the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009
   PubMed Web of Science ®Google Scholar
• Vonkorff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203
   PubMed Web of Science ®Google Scholar
• Lojkowska W, Ryglewicz D, Jedrzejczak T, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003;216:119-26
   PubMed Web of Science ®Google Scholar
• Gauthier S. Alzheimer's Disease in Primary Care. London: Informa Healthcare: 1999
   Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004;5:1399-410
   PubMed Web of Science ®Google Scholar
• Freo U, Pizzolato G, Carbonin C, et al. Effects of the acetylcholinesterase inhibitor rivastigmine in vascular dementia: results from a prospective pilot study. J Neurol Sci 2002;00:203-4
   Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004;5:1399-410
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27
   PubMed Web of Science ®Google Scholar
• Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89
   PubMed Web of Science ®Google Scholar
• Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67
   PubMed Web of Science ®Google Scholar
• Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6
   PubMed Web of Science ®Google Scholar
• Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004;20:1747-52
   PubMed Web of Science ®Google Scholar
• Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004;11:e274-85
   PubMedGoogle Scholar